Skip to main content

This website contains promotional content and is intended for Healthcare Professionals

Smoldering disease is a key unaddressed component of MS, driving disease progressions1-3

The Silent Progression in MS: Smoldering neuroinflammation and PIRA 

Acute Neuroinflammation

Acute neuroinflammation is driven in party by activated B cells and T cells derived from the periphery
    • Leads to relapses,acute lesions, and RAW1,8,11

10%-20% of disability accumulation in treated patients is driven by relapses and acute lesions 12,13

Smoldering Neuroinflammation

Smoldering neuroinflammation is driven in primarily by disease-associated microglia found in the CNS1,8,11
    • Leads to PIRA,resulting in physical disability and cognitive worsening1,8,11

80%-90% of disability accumulation in treated patients is relapse-independent and driven by smoldering neuroinflammation.12,13

Both concurrent neuroinflammatory processes drive disability accumulation in MS 1,14-16

Smoldering neuroinflammation starts at disease onset and increasingly drives disability accumulation1

The relative contribution of both acute and smoldering neuroinflammation shifts as patients progress from RRMS to nrSPMS1,14

  • Smoldering neuroinflammation presents early and throughout:the spectrum of MS, before initial clinical symptoms.1,11
  • Over the course of MS, acute neuroinflammation may decline, but smoldering neuroinflammation persists in the absence of relapses and acute lesions1
  • Disability accumulation driven by smoldering neuroinflammation can:
    • Happen throughout the disease spectrum9
    • Affect any patient, regardless of the type of MS or if patients have a history of taking DMTs1
  • Smoldering neuronflammation is driven primarily by disease-associated microglia found in the CNS and contributes to both physical and cognitive disability accumulation1,17

For more information about Acute and Smoldering Inflammation, click on this link:

MAT-KW-2500337/v1/Sept2025